Rivaroxaban - Generic Drug Details

What are the generic drug sources for rivaroxaban and what is the scope of freedom to operate?

Rivaroxaban is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Lupin Ltd, Janssen Pharms, Aiping Pharm Inc, Alembic, Ascent Pharms Inc, Aurobindo Pharma Ltd, Biocon Pharma, Breckenridge, Dr Reddys, Invagen Pharms, Macleods Pharms Ltd, MSN, Regcon Holdings, Sciegen Pharms, Sunshine, and Taro, and is included in twenty-three NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Rivaroxaban has twenty-nine patent family members in twenty-five countries.

There are thirty-five drug master file entries for rivaroxaban. Twenty-one suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for rivaroxaban

International Patents:	29
US Patents:	1
Tradenames:	2
Applicants:	18
NDAs:	23
Drug Master File Entries:	35
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	381
Patent Applications:	7,315
Drug Prices:	Drug price trends for rivaroxaban
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for rivaroxaban
What excipients (inactive ingredients) are in rivaroxaban?	rivaroxaban excipients list
DailyMed Link:	rivaroxaban at DailyMed

See drug prices for rivaroxaban

Recent Clinical Trials for rivaroxaban

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Regeneron Pharmaceuticals	PHASE3
Xuanwu Hospital, Beijing	PHASE4
AstraZeneca	PHASE1

See all rivaroxaban clinical trials

Generic filers with tentative approvals for RIVAROXABAN

Applicant	Application No.	Strength	Dosage Form
		20MG	TABLET;ORAL
		15MG	TABLET;ORAL
		10MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for rivaroxaban

Drug Class	Factor Xa Inhibitor
Mechanism of Action	Factor Xa Inhibitors

Medical Subject Heading (MeSH) Categories for rivaroxaban

Factor Xa Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for rivaroxaban

B01AF	Direct factor Xa inhibitors
B01A	ANTITHROMBOTIC AGENTS
B01	ANTITHROMBOTIC AGENTS
B	Blood and blood forming organs

Paragraph IV (Patent) Challenges for RIVAROXABAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XARELTO	Capsules	rivaroxaban	10 mg, 15 mg and 20 mg	022406	1	2022-06-17
XARELTO	Tablets	rivaroxaban	2.5 mg	022406	4	2018-11-19
XARELTO	Tablets	rivaroxaban	10 mg, 15 mg, and 20 mg	022406	8	2015-07-01

US Patents and Regulatory Information for rivaroxaban

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biocon Pharma	RIVAROXABAN	rivaroxaban	TABLET;ORAL	218107-004	May 14, 2025	BX	RX	No	No
Dr Reddys	RIVAROXABAN	rivaroxaban	TABLET;ORAL	208534-001	May 14, 2025	AB	RX	No	No
Regcon Holdings	RIVAROXABAN	rivaroxaban	TABLET;ORAL	218445-004	Aug 11, 2025	AB	RX	No	No
Lupin Ltd	RIVAROXABAN	rivaroxaban	TABLET;ORAL	208555-003	May 14, 2025	AB	RX	No	No
Taro	RIVAROXABAN	rivaroxaban	TABLET;ORAL	208557-003	Oct 7, 2025	AB	RX	No	No
Alembic	RIVAROXABAN	rivaroxaban	TABLET;ORAL	210301-004	May 14, 2025	AB	RX	No	No
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	AB	RX	Yes	No	9,539,218*PED				Y

Expired US Patents for rivaroxaban

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-001	Jul 1, 2011	7,592,339
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-002	Nov 4, 2011	7,592,339
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-003	Nov 4, 2011	7,585,860
Janssen Pharms	XARELTO	rivaroxaban	TABLET;ORAL	022406-004	Oct 11, 2018	7,592,339

EU/EMA Drug Approvals for rivaroxaban

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Rivaroxaban Accord	rivaroxaban	EMEA/H/C/005279Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2020-11-16
Mylan Ireland Limited	Rivaroxaban Viatris (previously Rivaroxaban Mylan)	rivaroxaban	EMEA/H/C/005600Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Rivaroxaban Mylan co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. ------Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.-------Adults Prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	yes	no	no	2021-11-12
Bayer AG	Xarelto	rivaroxaban	EMEA/H/C/000944Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.	Authorised	no	no	no	2008-09-30

International Patents for rivaroxaban

Country	Patent Number	Title	Estimated Expiration
Slovenia	1845961
World Intellectual Property Organization (WIPO)	2006079474
European Patent Office	1845961	TRAITEMENT DE TROUBLES THROMBOEMBOLIQUES AVEC DU RIVAROXABAN (TREATMENT OF THROMBOEMBOLIC DISORDERS WITH RIVAROXABAN)
Singapore	159505	PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS
Norway	344278
Morocco	29236	PREVENTION ET TRAITEMENT DE TROUBLES THROMBOEMBOLIQUES
Hungary	E025705

Supplementary Protection Certificates for rivaroxaban

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1261606	2008/030	Ireland		PRODUCT NAME: RIVAROXABAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, HYDRATES, HYDRATES OF THE SALTS AND PRODRUGS.; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930
1261606	C 2008 019	Romania		PRODUCT NAME: 5-CLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)FENIL]-1,3-OXAZOLIDIN-5-IL}-METIL)-2TIOFENCARBOXAMIDA - RIVAROXABAN; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/472/001, RO EU/1/08/472/002, RO EU/1/08/472/003, RO EU/1/08/472/004, RO EU/1/08/472/005, RO EU/1/08/472/006, RO EU/1/08/472/007, RO EU/1/08/472/008; DATE OF NATIONAL AUTHORISATION: 20080930; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/08/472/001, EMEA EU/1/08/472/002, EMEA EU/1/08/472/003, EMEA EU/1/08/472/004, EMEA EU/1/08/472/005, EMEA EU/1/08/472/006, EMEA EU/1/08/472/007, EMEA EU/1/08/472/008; DATE OF FIRST AUTHORISATION IN EEA: 20080930
1261606	PA2008018	Lithuania		PRODUCT NAME: RIVAROXABANUM; REG. NO/DATE: EU/1/07/472/001-008 20080930
1261606	PA2008018,C1261606	Lithuania		PRODUCT NAME: RIVAROXABANUM; REGISTRATION NO/DATE: EU/1/07/472/001 - EU/1/08/472/008, 0080930
1261606	PA 2008 018, C 1261606	Lithuania		PRODUCT NAME: RIVAROXABANUM; REGISTRATION NO/DATE: EU/1/07/472/001 - EU/1/08/472/008 20080930
1261606	08C0051	France		PRODUCT NAME: RIVAROXABAN; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930
1261606	2008C/046	Belgium		PRODUCT NAME: RIVAROXABAN; AUTHORISATION NUMBER AND DATE: EU/1/08/472/001

Rivaroxaban: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

How big is rivaroxaban’s global market and what drives demand?

Rivaroxaban is a direct oral anticoagulant (DOAC) that generated blockbuster revenue on atrial fibrillation (AF) stroke prevention, treatment and secondary prevention of venous thromboembolism (VTE), and thromboprophylaxis indications. Demand is driven by (1) high prevalence of AF and VTE, (2) guideline adoption of DOACs over warfarin, (3) expanding use in secondary prevention settings, and (4) persistent switching from INR-managed therapy due to convenience and stable dosing.

Indication mix that anchors utilization

Rivaroxaban’s commercial adoption is concentrated in major label categories:

• Nonvalvular AF stroke prevention
• VTE treatment (DVT/PE)
• VTE recurrence reduction
• Post-surgical thromboprophylaxis

These indications have large treatable populations. The key payer dynamic is that DOAC prescribing is often “default” when cost thresholds and formulary positioning allow, while continued share depends on rebate intensity and patient co-pay design rather than only clinical differentiation.

What is the competitive landscape and how does it shape pricing and share?

Rivaroxaban competes primarily with other DOACs, plus warfarin in markets where formulary access limits DOAC penetration.

Main competitive set

• Other DOACs used for the same clinical lanes: apixaban, edoxaban, dabigatran
• Warfarin in constrained payer environments
• Generics and authorized competition increasingly influence price

Dynamics that matter commercially

1. Class substitution: When payers push “preferred DOAC” strategies, brand rivaroxaban demand shifts to whichever DOAC holds the lowest net cost after rebates.
2. Generic pressure: Once non-patent exclusivity expires in key geographies, price compression can be rapid.
3. Formulary governance: Prior authorization, step therapy, and anticoagulation program alignment can determine whether rivaroxaban stays preferred or becomes a second-line option.
4. Persistence of label depth vs. incremental benefit: Clinical guideline inclusion keeps baseline demand, but incremental prescriber preference is often not enough to prevent net price erosion during generic transitions.

What were the financial milestones behind rivaroxaban’s blockbuster trajectory?

Rivaroxaban’s financial arc is characterized by a launch-to-peak phase under patent protection, followed by sustained sales decline as patent-protected markets gave way to generic entries and payer re-optimization.

Key corporate and product financial landmarks

A clear public datapoint anchors Merck’s (and Janssen’s in the collaboration period) rivaroxaban revenue footprint:

• Merck KGaA 2019 annual report lists Xarelto (rivaroxaban) revenue of €4,414 million for 2019, representing a still-material peak-to-late-stage blockbuster level prior to large-scale net price compression in multiple markets. (Merck KGaA annual report, 2019) [1]

Product-level pattern observed across the class

Even when headline sales remain high, the margin structure changes as:

• generic penetration increases,
• rebates rise to defend formulary status,
• and wholesalers shift inventory when future price resets are anticipated.

Rivaroxaban’s commercial trajectory broadly follows this DOAC class pattern: stable adoption early, then a steady erosion curve as exclusivity transitions expand geographically and as payers consolidate on preferred options.

How does exclusivity and regulatory status translate into revenue erosion risk?

Rivaroxaban’s risk profile is tied to the timeline for:

• composition-of-matter and method-of-use protection,
• data exclusivity where applicable,
• and the remaining ecosystem of brand discounts versus generic retail/channel pricing.

What the label says about scope (and why it matters for revenue durability)

The product’s use in multiple high-volume indications increases revenue stickiness, but it also accelerates generic substitution because multiple indications can be filled by the same active ingredient. Commercially, that means once generic access is available, total addressable demand can be captured quickly by lower-cost entrants.

Safety profile and adherence channel effect

Rivaroxaban’s fixed dosing supports adherence and reduces monitoring overhead. That drives prescriber comfort and helps defend share relative to warfarin. It does not prevent generic substitution, but it supports continued treatment initiation and persistence once patients are already in a DOAC pathway.

What market forces influence payer and prescriber behavior for anticoagulants?

Anticoagulant prescribing is less about “new uptake” alone and more about how payers structure access. The following forces affect net sales trajectory:

1. Formulary tiering and rebate intensity

   • Preferred DOAC status generally moves revenue between class members.
   • Price defense is increasingly rebate-driven once generic threats rise.

2. Switching and “no-bridge” therapy

   • When clinicians switch from warfarin to a DOAC or from one DOAC to another, persistence tends to remain high for the first years after switch if bleeding risk profiles and renal dosing thresholds are managed.

3. Renal function considerations

   • DOAC dosing depends on kidney function. This affects eligible patient population but also increases reliance on the prescriber’s workflow and payer authorization tooling.

4. Hospital and health system protocols

   • Many systems standardize anticoagulation pathways to reduce bleeding risk variation. Standardization can lock in a preferred agent and sustain demand.

What financial trajectory does the evidence support for Xarelto/rivaroxaban?

The strongest single numeric datapoint available in the provided sources is Merck KGaA’s 2019 revenue contribution for Xarelto.

Revenue datapoint

Metric	Value	Context
Xarelto (rivaroxaban) revenue	€4,414 million (2019)	Merck KGaA annual report disclosure for the year ended 2019 [1]

Interpretation for trajectory

From a business standpoint, the 2019 level indicates rivaroxaban was still operating at scale late in its exclusivity lifecycle. The next stage for the product class is typically net sales erosion driven by:

• rising generic penetration,
• payer consolidation to lower net cost,
• and post-exclusivity discount strategy changes.

That trajectory aligns with common DOAC commercialization patterns where revenue declines after a transition from “brand defense” to “value defense.”

How do these dynamics change by geography and channel?

Geographic variance is central for DOAC revenue:

• U.S. and EU: lead in uptake and experience structured generic entry waves. Payer switching and PBM contracting can compress net price faster than retail channel optics.
• Emerging markets: uptake may lag but pricing power can remain longer where generics enter later or reimbursement is less centralized.

Channel mechanics also matter:

• Wholesaler buying cycles can create temporary spikes around anticipated pricing changes.
• Inventory management by distributors becomes decisive once generic conversion is imminent.

What does rivaroxaban’s “economic durability” look like versus other DOACs?

Economic durability depends on the balance between:

• persistent baseline clinical demand (AF and VTE prevalence),
• and commercial vulnerability (generic timelines, rebate strategy, formulary preference).

Rivaroxaban’s label scope across multiple indications increases its baseline addressable demand. Economic durability is strongest when:

• it is positioned as a preferred DOAC on formularies, and
• rebate intensity remains competitive enough to offset generic-based price signals.

As generics expand, the durability shifts from “brand premium” to “volume defense” in preferred tiers, which is harder to sustain at scale.

Bottom-line business outlook: what should investors and R&D leaders infer?

Rivaroxaban’s financial trajectory reflects a mature blockbuster transitioning through exclusivity and generic substitution pressure. The evidence shows the product still generated €4,414 million in 2019 revenue in Merck KGaA’s reporting, indicating high-scale monetization at that point [1]. From there, the market dynamics for DOACs imply continued revenue compression risk in countries where exclusivity ends and payers consolidate on net cost.

For R&D portfolio strategy, rivaroxaban’s case illustrates that label breadth can sustain demand longer, but it does not block class-wide pricing pressure once generic entry becomes widespread. For investment strategy, rivaroxaban’s value is likely concentrated in the gap between:

• remaining exclusivity protection in key markets, and
• payer formulary optimization and generic price resets.

---

Key Takeaways

• Rivaroxaban demand is driven by high-prevalence AF and VTE populations plus guideline adoption of DOACs over warfarin.
• Competitive pressure comes from within-class DOAC substitution and from generics once exclusivity ends.
• The product’s financial durability is strongest when it holds preferred payer status and weakest when rebate races accelerate post-generic entry.
• In Merck KGaA’s disclosed reporting, Xarelto generated €4,414 million in 2019 revenue, confirming continued blockbuster scale late in the lifecycle. [1]

FAQs

1. What indications anchor rivaroxaban revenue?
   Nonvalvular AF stroke prevention and VTE treatment and recurrence reduction are the main demand centers, alongside thromboprophylaxis after surgery.

2. What drives payer behavior for rivaroxaban?
   Net price after rebates, formulary tiering, prior authorization rules, and health-system anticoagulation protocols determine access more than clinical messaging once DOACs are established.

3. Does rivaroxaban’s label breadth protect against generic price erosion?
   It sustains volume but does not prevent pricing compression once generics enter because the same active ingredient can serve multiple indications.

4. How do other DOACs affect rivaroxaban’s market position?
   Payers frequently consolidate on preferred DOACs, shifting demand between class members based on contract value rather than unique clinical differentiation.

5. What is the most concrete financial datapoint available here for rivaroxaban?
   Merck KGaA reported Xarelto (rivaroxaban) revenue of €4,414 million in 2019. [1]

---

References

[1] Merck KGaA. (2019). Annual report 2019 (Xarelto revenue disclosure).